144 related articles for article (PubMed ID: 38386272)
1. Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor
Kaneko K; Nagao M; Ueda K; Yamamoto A; Sakai S
Ann Nucl Med; 2024 Apr; 38(4):278-287. PubMed ID: 38386272
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of
Yomo S; Oguchi K
BMC Cancer; 2017 Nov; 17(1):713. PubMed ID: 29110648
[TBL] [Abstract][Full Text] [Related]
3. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.
Tsuyuguchi N; Takami T; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Nishikawa M; Ohata K; Torii K; Morino M; Nishio A; Hara M
Ann Nucl Med; 2004 Jun; 18(4):291-6. PubMed ID: 15359921
[TBL] [Abstract][Full Text] [Related]
4. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?
Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M
J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and
Qiao Z; Zhao X; Wang K; Zhang Y; Fan D; Yu T; Shen H; Chen Q; Ai L
AJNR Am J Neuroradiol; 2019 Feb; 40(2):253-259. PubMed ID: 30655259
[TBL] [Abstract][Full Text] [Related]
7. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among
Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y
AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837
[TBL] [Abstract][Full Text] [Related]
8. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions.
Okamoto S; Shiga T; Hattori N; Kubo N; Takei T; Katoh N; Sawamura Y; Nishijima K; Kuge Y; Tamaki N
Ann Nucl Med; 2011 Apr; 25(3):213-20. PubMed ID: 21188660
[TBL] [Abstract][Full Text] [Related]
9. Optimization of scan initiation timing after
Nakajima R; Abe K; Momose M; Fukushima K; Matsuo Y; Kimura K; Kondo C; Sakai S
Ann Nucl Med; 2017 Feb; 31(2):190-197. PubMed ID: 27885545
[TBL] [Abstract][Full Text] [Related]
10. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
11. Reliability of Magnetic Resonance Spectroscopy and Positron Emission Tomography Computed Tomography in Differentiating Metastatic Brain Tumor Recurrence from Radiation Necrosis.
Travers S; Joshi K; Miller DC; Singh A; Nada A; Biedermann G; Cousins JP; Litofsky NS
World Neurosurg; 2021 Jul; 151():e1059-e1068. PubMed ID: 34052453
[TBL] [Abstract][Full Text] [Related]
12. [
Tran TT; Gallezot JD; Jilaveanu LB; Zito C; Turcu G; Lim K; Nabulsi N; Huang H; Huttner A; Kluger HM; Chiang VL; Carson R
Mol Imaging; 2020; 19():1536012120968669. PubMed ID: 33147119
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
[TBL] [Abstract][Full Text] [Related]
14. Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography.
Park JE; Lee JY; Kim HS; Oh JY; Jung SC; Kim SJ; Keupp J; Oh M; Kim JS
Eur Radiol; 2018 Aug; 28(8):3285-3295. PubMed ID: 29488086
[TBL] [Abstract][Full Text] [Related]
15. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
16. 11 C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11 C-Methionine PET/CT in Glioma Classification and Survival Prediction.
Kim D; Yi JH; Park Y; Kim SJ; Kang SG; Kim SH; Chun JH; Chang JH; Yun M
Clin Nucl Med; 2024 Feb; 49(2):109-115. PubMed ID: 38049976
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment.
Minamimoto R; Saginoya T; Kondo C; Tomura N; Ito K; Matsuo Y; Matsunaga S; Shuto T; Akabane A; Miyata Y; Sakai S; Kubota K
PLoS One; 2015; 10(7):e0132515. PubMed ID: 26167681
[TBL] [Abstract][Full Text] [Related]
18. Re-evaluation of the diagnostic performance of
Kim D; Chun JH; Kim SH; Moon JH; Kang SG; Chang JH; Yun M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1678-1684. PubMed ID: 31102001
[TBL] [Abstract][Full Text] [Related]
19. Methionine-PET to differentiate between brain lesions appearing similar on conventional CT/MRI scans.
Ohmura K; Ikegame Y; Yano H; Shinoda J; Iwama T
J Neuroimaging; 2023; 33(5):837-844. PubMed ID: 37246342
[TBL] [Abstract][Full Text] [Related]
20. Determination of brain tumor recurrence using
Yamaguchi S; Hirata K; Okamoto M; Shimosegawa E; Hatazawa J; Hirayama R; Kagawa N; Kishima H; Oriuchi N; Fujii M; Kobayashi K; Kobayashi H; Terasaka S; Nishijima KI; Kuge Y; Ito YM; Nishihara H; Tamaki N; Shiga T
Cancer Sci; 2021 Oct; 112(10):4246-4256. PubMed ID: 34061417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
